1
The standard group patients received 48 weeks of peginterferon plus ribavirin treatment.
2
None of the studied patients received ribavirin therapy or specific RSV immunoglobulin.
3
This data supports further evaluation of VCH-759 in combination with interferon-ribavirin treatment.
4
The proposed algorithm also holds for patients treated with peg-interferon and ribavirin.
5
Typical treatment involves 52 weeks of interferon plus the antiviral drug ribavirin.
1
In the multivariate Cox analysis, RBV ranges remained independent and significant outcome predictors.
2
No additional benefits of RBV use were observed for both regimens.
3
Selection towards a dominant IFN-resistant strain did not occur under standard or PEG-IFN plus RBV.
4
Conclusion: Quantitative whole-animal absorption reconstruction is possible and can be validated in vivo using the rBV.
5
Only individuals who had completed a course of pegIFN-RBV therapy and had validated outcomes were considered.